NASDAQ:LPCN Lipocine (LPCN) Stock Forecast, Price & News $4.30 -0.13 (-2.93%) (As of 04:33 PM ET) Add Compare Share Share Today's Range$4.30▼$4.5650-Day Range$3.53▼$5.4752-Week Range$3.30▼$15.44Volume9,490 shsAverage Volume19,193 shsMarket Capitalization$22.36 millionP/E RatioN/ADividend YieldN/APrice Target$68.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Lipocine MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside1,481.4% Upside$68.00 Price TargetShort InterestHealthy1.58% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 3 Articles This WeekInsider TradingAcquiring Shares$109,646 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.42) to ($1.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.73 out of 5 starsMedical Sector820th out of 986 stocksPharmaceutical Preparations Industry400th out of 479 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $68.00, Lipocine has a forecasted upside of 1,481.4% from its current price of $4.30.Amount of Analyst CoverageLipocine has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.58% of the float of Lipocine has been sold short.Short Interest Ratio / Days to CoverLipocine has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipocine has recently increased by 31.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLipocine does not currently pay a dividend.Dividend GrowthLipocine does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LPCN. Previous Next 2.4 News and Social Media Coverage News SentimentLipocine has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lipocine this week, compared to 1 article on an average week.Search Interest11 people have searched for LPCN on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Lipocine to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lipocine insiders have bought more of their company's stock than they have sold. Specifically, they have bought $109,646.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Lipocine is held by insiders.Percentage Held by InstitutionsOnly 12.18% of the stock of Lipocine is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lipocine are expected to grow in the coming year, from ($2.42) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lipocine is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lipocine is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLipocine has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lipocine (NASDAQ:LPCN) StockLipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.Read More Receive LPCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter. Email Address LPCN Stock News HeadlinesJune 9, 2023 | americanbankingnews.comLipocine (NASDAQ:LPCN) Receives New Coverage from Analysts at StockNews.comJune 7, 2023 | finance.yahoo.comLipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023June 9, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.June 1, 2023 | americanbankingnews.comLipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.comMay 27, 2023 | americanbankingnews.comMahesh V. Patel Buys 8,706 Shares of Lipocine Inc. (NASDAQ:LPCN) StockMay 24, 2023 | americanbankingnews.comEquities Analysts Offer Predictions for Lipocine Inc.'s FY2023 Earnings (NASDAQ:LPCN)May 18, 2023 | americanbankingnews.comLipocine Inc. (NASDAQ:LPCN) Sees Large Decrease in Short InterestMay 17, 2023 | americanbankingnews.comLipocine (NASDAQ:LPCN) Earns Buy Rating from Analysts at StockNews.comJune 9, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 16, 2023 | msn.comLipocine stock dips after bridging study data of LPCN 1154 for postpartum depressionMay 16, 2023 | finance.yahoo.comPositive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of DepressionMay 12, 2023 | msn.comRecap: Lipocine Q1 EarningsMay 11, 2023 | apnews.comLipocine: Q1 Earnings SnapshotMay 11, 2023 | finance.yahoo.comLipocine Announces Financial Results for the First Quarter Ended March 31, 2023May 9, 2023 | americanbankingnews.comLipocine (NASDAQ:LPCN) Now Covered by StockNews.comMay 8, 2023 | americanbankingnews.comLipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.comMay 1, 2023 | americanbankingnews.comLipocine (NASDAQ:LPCN) Research Coverage Started at StockNews.comApril 23, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)April 10, 2023 | americanbankingnews.comHead-To-Head Comparison: Protagonist Therapeutics (NASDAQ:PTGX) versus Lipocine (NASDAQ:LPCN)April 3, 2023 | finance.yahoo.comFirst Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154March 25, 2023 | americanbankingnews.comLipocine Inc. (NASDAQ:LPCN) CEO Mahesh V. Patel Acquires 150,000 SharesMarch 21, 2023 | americanbankingnews.comLipocine Inc. Expected to Post FY2023 Earnings of ($0.15) Per Share (NASDAQ:LPCN)March 16, 2023 | finance.yahoo.comLPCN: 2022 Operational & Financial UpdateMarch 10, 2023 | finance.yahoo.comLipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common StockMarch 10, 2023 | finance.yahoo.comLipocine Announces Financial Results for the Year Ended December 31, 2022January 16, 2023 | finance.yahoo.comIs Lipocine Inc.'s (NASDAQ:LPCN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?January 5, 2023 | finance.yahoo.comLipocine to Present at Biotech ShowcaseSee More Headlines LPCN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LPCN Company Calendar Last Earnings3/10/2023Today6/09/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LPCN CUSIPN/A CIK1535955 Webwww.lipocine.com Phone(801) 994-7383Fax801-994-7388Employees13Year Founded1997Price Target and Rating Average Stock Price Forecast$68.00 High Stock Price Forecast$68.00 Low Stock Price Forecast$68.00 Forecasted Upside/Downside+1,391.2%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($2.3809) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,760,000.00 Net MarginsN/A Pretax Margin-2,007.21% Return on Equity-30.70% Return on Assets-29.09% Debt Debt-to-Equity RatioN/A Current Ratio15.86 Quick Ratio15.86 Sales & Book Value Annual Sales$500,000.00 Price / Sales47.42 Cash FlowN/A Price / Cash FlowN/A Book Value$6.85 per share Price / Book0.67Miscellaneous Outstanding Shares5,200,000Free Float4,944,000Market Cap$23.71 million OptionableOptionable Beta0.95 Social Links Key ExecutivesMahesh V. PatelPresident, Chief Executive Officer & DirectorGeorge G NomikosChief Medical OfficerAnthony DelConteChief Medical DirectorNachiappan ChidambaramVice President-Product DevelopmentKrista FogartyChief Accounting OfficerKey CompetitorsMetacrineNASDAQ:MTCRAcasti PharmaNASDAQ:ACSTVaccinexNASDAQ:VCNXUnicycive TherapeuticsNASDAQ:UNCYOnconova TherapeuticsNASDAQ:ONTXView All CompetitorsInsiders & InstitutionsEP Wealth Advisors LLCBought 66,983 shares on 6/5/2023Ownership: 1.288%Mahesh V PatelBought 8,706 shares on 5/25/2023Total: $43,791.18 ($5.03/share)Two Sigma Investments LPSold 35,304 shares on 5/15/2023Ownership: 4.880%Price T Rowe Associates Inc. MDSold 10,062 shares on 5/15/2023Ownership: 3.355%Two Sigma Advisers LPSold 30,500 shares on 5/15/2023Ownership: 2.537%View All Insider TransactionsView All Institutional Transactions LPCN Stock - Frequently Asked Questions What is Lipocine's stock price forecast for 2023? 0 brokers have issued twelve-month target prices for Lipocine's stock. Their LPCN share price forecasts range from $68.00 to $68.00. On average, they predict the company's stock price to reach $68.00 in the next twelve months. This suggests a possible upside of 1,391.2% from the stock's current price. View analysts price targets for LPCN or view top-rated stocks among Wall Street analysts. How have LPCN shares performed in 2023? Lipocine's stock was trading at $6.7626 at the start of the year. Since then, LPCN stock has decreased by 32.6% and is now trading at $4.56. View the best growth stocks for 2023 here. Are investors shorting Lipocine? Lipocine saw a increase in short interest in May. As of May 15th, there was short interest totaling 80,100 shares, an increase of 32.0% from the April 30th total of 60,700 shares. Based on an average daily trading volume, of 26,100 shares, the days-to-cover ratio is presently 3.1 days. Approximately 1.6% of the company's stock are sold short. View Lipocine's Short Interest. When is Lipocine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our LPCN earnings forecast. How were Lipocine's earnings last quarter? Lipocine Inc. (NASDAQ:LPCN) issued its quarterly earnings results on Friday, March, 10th. The specialty pharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter. When did Lipocine's stock split? Shares of Lipocine reverse split before market open on Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of Lipocine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX). What is Lipocine's stock symbol? Lipocine trades on the NASDAQ under the ticker symbol "LPCN." Who are Lipocine's major shareholders? Lipocine's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.66%), Wealth Effects LLC (0.85%), Two Sigma Investments LP (4.88%), Price T Rowe Associates Inc. MD (3.36%), Two Sigma Advisers LP (2.54%) and EP Wealth Advisors LLC (1.29%). Insiders that own company stock include John W Higuchi, Krista Fogarty, Mahesh V Patel, Morgan R Brown, Richard Dana Ono and Spyros Papapetropoulos. View institutional ownership trends. How do I buy shares of Lipocine? Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lipocine's stock price today? One share of LPCN stock can currently be purchased for approximately $4.56. How much money does Lipocine make? Lipocine (NASDAQ:LPCN) has a market capitalization of $23.71 million and generates $500,000.00 in revenue each year. The specialty pharmaceutical company earns $-10,760,000.00 in net income (profit) each year or ($2.3809) on an earnings per share basis. How can I contact Lipocine? Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The official website for the company is www.lipocine.com. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at john.woolford@westwicke.co, or via fax at 801-994-7388. This page (NASDAQ:LPCN) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.